Controversial U.K. researcher says drug laws amount to scientific censorship; Bionor shares surge on HIV study;

@FierceBiotech: Report: Genomics industry contributed $1 trillion to U.S. economy in last 25 years. Article | Follow @FierceBiotech

 @JohnCFierce: Royalty Pharma scrambles to salvage vote on hostile Elan takeover. Story | Follow @JohnCFierce

@RyanMFierce: GSK has halted a study of an MS compound linked to data fraud in China. The plot thickens. More | Follow @RyanMFierce

 @EmilyMFierce: SCOTUS decision on Myriad case: Natural isolated DNA is not patentable. Synthetic DNA is patentable because it doesn't occur naturally. | Follow @EmilyMFierce

> The controversial U.K. researcher David Nutt has lambasted the move to outlaw drugs like magic mushrooms, saying the dangers were overstated and that the laws created "the worst case of scientific censorship since the Catholic Church banned the works of Copernicus and Galileo." Nutt has been struggling to launch new trials that would test the clinical efficacy of agents like psilocybin. Story

> Shares of Norway's Bionor Pharma surged after it completed one leg of a study matching its Vacc-4x HIV vaccine with Celgene's ($CELG) Revlimid. Story

Medical Device News

@FierceMedDev: Life Tech buys Korean distributor as Thermo waits. News | Follow @FierceMedDev

@DamianFierce: Venture-backed Natera is expanding its prenatal test as it contends with $SQNM, $ILMN and others. Article | Follow @DamianFierce

@MarkHFierce: Just met in Berlin with Christian Pangratz, CBO of Activaero, which has a promising drug-device liquid inhalation treatment for asthma. | Follow @MarkHFierce

@MichaelGFierce: Chime in on the nano-gold discussion at the FierceBiotech LinkedIn page: Discussion | Follow @MichaelGFierce

> FDA wants tighter cybersecurity for medical devices. More

> Mindray commits $105M to grab U.S. ultrasound imaging company. News

> For heart disease diagnosis, two tests may be better than one. DxExtra

Pharma News

@FiercePharma: Catalent kicks off $35M expansion in U.S. More | Follow @FiercePharma

@EricPFierce: Novo suggests overzealous reading of risks of Type 2 diabetes drugs that include Victoza, Januvia. Article | Follow @EricPFierce

@CarlyHFierce: Insider trading charges from Sanofi/Chattem deal continue to pile up. Brothers allegedly scored a $50k profit. Report | Follow @CarlyHFierce

> GSK probes sales tactics in China days after firing R&D chief there. More

> AARP fears Pfizer tactics to defend Lipitor could become model. Story

Pharma Manufacturing News

> Zydus recalls wafarin after oversized tablets discovered. Item

> FedEx vows not to settle with feds on online pharmacy shipments. Story

> FDA warning letter nails 2 Baxter plants for repeat violations. Article

> FDA comes down on another Indian drugmaker. Report

Vaccines News

> Latin American cancer vax races Big Pharma rivals. More

> FDA clears Sanofi to compete for 4-in-1 flu vaccine market. Report

> FDA setback sends Dynavax shares tumbling again. Article

> Oral vaccine aims to end dreaded Delhi belly. Story

And Finally… Researchers at Mt. Sinai Medical Center say that numerous drug classes can influence the development of Alzheimer's. Release

Suggested Articles

The deal, which features an additional $2 billion in milestones, will give Bayer control of an AAV platform and a clinical-phase pipeline.

Scorpion is working on precision oncology 2.0, which includes making better drugs for known targets, hit undruggable targets and discover new targets.

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.